Pharmacogenetics: The therapeutic drug monitoring of the future?

Clinical Pharmacokinetics

Volumn 40, Issue 11, 2001, Pages 783-802

  Ensom, M H H ^a,b   Chang, T K H ^a   Patel, P ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AZATHIOPRINE; CLOZAPINE; CODEINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIGOXIN; DRUG METABOLIZING ENZYME; IFOSFAMIDE; MERCAPTOPURINE; ORAL ANTIDIABETIC AGENT; PHENYTOIN; TACRINE; THEOPHYLLINE; TIOGUANINE; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; GENETIC VARIABILITY; GENOTYPE; NON INVASIVE MEASUREMENT; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; STEADY STATE; TOXICITY;

EID: 0035183513     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140110-00001     Document Type: Review

References (199)

1. Clinical pharmacokinetics in the 21st century: Does the evidence support definitive outcomes?
2. Opportunities and responsibilities in pharmaceutical care
3. A Bayesian feedback method of aminoglycoside dosing
4. Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: The optimal use of intravenously administered theophylline
5. Computer-assisted individualized lidocaine dosage: Clinical evaluation and comparison with physician performance
6. Anticonvulsant serum levels are useful only if the physician appropriately uses them: An assessment of the impact of providing serum level data to physicians
7. Clinical pharmacokinetics: A comprehensive system for therapeutic drug monitoring and prescribing
8. Individualized theophylline therapy: The impact of clinical pharmacokinetics on patient outcomes
9. Pharmacist based iv theophylline therapy
10. A randomized controlled clinical trial of pharmacokinetic theophylline dosing
11. Impact of decentralized pharmacokinetics consultation service
12. Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods
13. Serial pharmacokinetic dosing of aminoglycosides: A community hospital experience
14. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections
15. Evaluation of a digoxin pharmacokinetic monitoring service in a community hospital
16. Challenges in comparing treatment outcome from a prospective with that of a retrospective study: Assessing the merit of gentamicin therapeutic drug monitoring in pediatric oncology
17. Establishing an aminoglycoside pharmacokinetic monitoring service in a community hospital
18. An evaluation of a clinical pharmacokinetic service for serum digoxin levels
19. Evaluation of a therapeutic drug monitoring program for theophylline in a teaching hospital
20. Seven years of experience with a pharmacokinetic service
21. The history of a comprehensive pharmacokinetic service
22. Meta-analysis of research on the effect of clinical pharmacokinetics services on therapeutic drug monitoring
23. The impact of a therapeutic drug monitoring program for phenytoin
24. Impact of therapeutic drug monitoring of intravenous theophylline regimens on serum theophylline concentrations in the medical intensive care unit
25. Cost analysis of an aminoglycoside pharmacokinetic dosing program
26. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service
27. Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: A cost-benefit analysis
28. Increased burn patient survival with individualized dosages of gentamicin
29. Outcome of patients treated by an aminoglycoside pharmacokinetic dosing service
30. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization
31. Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: A cost-benefit analysis
32. Does accepting pharmacokinetic recommendations impact hospitalization?: A cost-benefit analysis
33. Effect of individualized pharmacokinetic dosing on patient outcome
34. A controlled trial of the cost benefit of computerized Bayesian aminoglycoside administration
35. Impact of a pharmacokinetics consultation service on clinical outcomes in an ambulatory-care epilepsy clinic
36. Therapeutic drug monitoring in a paediatric epilepsy clinic
37. The relevance of a first-world therapeutic drug monitoring service to the treatment of epilepsy in third-world conditions
38. Reduction of digoxin toxicity associated with measurement of serum levels
39. Impact of vancomycin therapeutic drug monitoring on patient care
40. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies
41. Cost-benefit analysis of an aminoglycoside monitoring service
42. Aminoglycoside monitoring: Use of a pharmacokinetic service versus physician recommendations
43. Individualized pharmacokinetic versus standard dosing of amikacin: A comparison of therapeutic outcomes
44. A utilization and cost-benefit analysis of an aminoglycoside kinetics monitoring service
45. Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy?
46. Effect of theophylline pharmacokinetic monitoring service on cost and quality of care
47. A randomized controlled trial of computerized pharmacokinetic theophylline dosing versus empiric physician dosing
48. Impact of pharmacogenomics on the clinical laboratory
49. Pharmacogenomics: Worthy of pharmacy's attention
50. Inventing the pharmacogenomics business
51. Pharmacogenetics and pharmacogenomics: Why is this relevant to the clinic
52. Pharmacogenomics: Translating functional genomics into rational therapeutics
53. Human Genome Project and pharmacogenomics: Implications for pharmacy
54. The Human Genome Project
55. Drug therapy and pharmacogenomics
56. Genomics and proteomics in drug discovery and development
57. Pharmacogenomics: The promise of personalized medicine
58. Clinical trials in pharmacogenetics and pharmacogenomics: Methods and applications
59. Genetic variation as a guide to drug development
60. Pharmacogenomics: A new approach to individual therapy of hypertension?
61. The business of pharmacogenomics
62. Pharmacogenomics: Today, tomorrow, and beyond
63. Pharmacogenetics becomes pharmacogenomics: Wake up and get ready
64. Pharmacogenomics: Tailoring drug therapy
65. Pharmacogenomics and the changing face of clinical pharmacology
66. Technologies for detecting genetic polymorphisms in pharmacogenomics
67. Enzymatic deficiency in primaquine-sensitive erythrocytes
68. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis
69. Moderne probleme der humangenetik
70. Shattuck lecture - Medical and societal consequences of the Human Genome Project
71. The sequence of the human genome
72. New technologies and DNA resources for high throughput biology
73. DNA chips: The future of biomarkers
74. High throughput and global approaches to gene expression
75. Transitions: Part 1. Beyond pharmaceutical care
76. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment
77. Pharmacogenomics: Tailoring the drug to the patient
78. Collaboration between pharmacy and laboratory: Defining total allowable error limits for therapeutically monitored drugs
79. Why pharmacogenomics? Why now?
80. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype
81. Pharmacogenetics and psychopharmacotherapy
82. Therapeutic drug monitoring of psychotropic medications
83. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry
84. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A
85. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
86. Polymorphic hydroxylation of debrisoquine in man
87. Purification and characterization of the human liver cytochrome P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism
88. Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization
89. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs
90. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations
91. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
92. The CYP2C19 polymorphism
93. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
94. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese
95. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helibactor pylori eradication in cytochrome P450 2C19 poor metabolizers
96. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori
97. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans
98. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
99. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection
100. Cytochrome P450 2C9: An enzyme of major importance in human drug metablism
101. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily
102. 359 allelic variant in the tolbutamide polymorphism
103. 359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation
104. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome
105. Genetic analysis of the human cytochrome P450 CYP2C9 locus
106. Genetic analysis of CYP2C9 polymorphism in a Japanese population
107. Allelic and functional variability of cytochrome P450 2C9
108. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles county
109. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
110. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis
111. 359 variants: Enzyme kinetic study with seven substrates
112. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance
113. Pharmacogenetics of the human arylamine N-acetyltransferases
114. Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance
115. Human acetyl-transferase polymorphisms
116. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism
117. In vitro formation, disposition and toxicity of N-acetoxy-sulfamethoxazole, a potential mediator of sulfamethoxazole toxicity
118. Molecular mechanism of slow acetylation of drugs and carcinogens in humans
119. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing
120. The genetics of asthma: Implications for clinical practice
121. The physiological function of drug-transporting P-glycoproteins
122. Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors
123. Biochemical, cellular and pharmacological aspects of the multidrug transporter
124. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
125. Pharmacogenetics of cancer therapy: Getting personal
126. Thiopurine S-methyl-transferase deficiency: Two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians
127. Trastuzumab, a recombinant DNA derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
128. Recombinant humanized anti-HER2 antibody (HERCEPTIN) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
129. Pharmacogenomics at work
130. Apolipoprotein E genotype and gender influence response to tacrine therapy
131. Pharmacogenetics
132. The risk and severity of bleeding complications in elderly patients treated with warfarin
133. Factors affecting the maintenance dose of warfarin
134. High clearance of (S)-warfarin in a warfarin resistant subject
135. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-450 2C9 in the etiology of (S)-warfarin-drug interaction
136. Impaired S-warfarin metabolism catalyzed by R144C allelic variant of CYP2C9
137. Allelic variants of human cytochrome P-450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity and prochiral selectivity of the wild-type and I359L mutant forms
138. 359Leu) of cytochrome P450 2C9 in the oxidation of tolbutamide and warfarin by human liver microsomes
139. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprogen, and diclofenac by human liver microsomes
140. 359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
141. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
142. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
143. Stereoselective 4′-hydroxylation of phenytoin: Relationship to (S)-mephenytoin polymorphism in Japanese
144. Roles of cytochrome P450 2C9 and cytochrome P450 2C19 in the stereoselective metabolism of phenytoin to its major metabolite
145. Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity
146. Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: The role of genetic factors
147. Inheritance of phenytoin hypometabolism: A kinetic study of one family
148. Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family
149. Phenytoin hydroxylation in a healthy Caucasian population: Bimodal distribution of hydroxyphenytoin urinary excretion
150. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
151. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics
152. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication
153. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using singlestrand conformation polymorphism analysis
154. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus
155. Properties of opiate-receptor binding in rat brain
156. Polymorphic O-demethylation of codeine
157. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 db1/buf1)
158. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation
159. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
160. Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects
161. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions
162. Effect of codeine on gastroinestinal motility in relation to CYP2D6 phenotype
163. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation
164. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine
165. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae
166. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes
167. Pharmacogenetics of tolbutamide metabolism in humans
168. Severe prolonged hypoglycemia following tolbutamide and carbutamide treatment
169. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene
170. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
171. Clinical implications of antidepressant pharmacokinetics and pharmacogenetics
172. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
173. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes
174. High blood concentrations of imipramine or clomipramine and therapeutic failure: A case report using drug monitoring data
175. Extremely rapid hydroxylation of debrisoquine: A case report with implication for treatment with nortriptyline and other tricyclic antidepressants
176. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
177. Antidepressants and drug-metabolizing enzymes: Expert group report
178. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness
179. Susceptibility mutations in the mitochondrial small ribosomal RNA gene in aminoglycoside induced deafness
180. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity
181. The MDRI gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin
182. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
183. Human P-glycoprotein transports cyclosporin A and FK506
184. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
185. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance
186. Metabolism of theophylline by cDNA-expressed human cytochromes P-450
187. Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese
188. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
189. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
190. Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine
191. Pharmacogenetic prediction of clozapine response
192. Screening for factor V Leiden mutation before prescribing combination oral contraceptives
193. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital
194. Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
195. Science, medicine, and the future: Pharmacogenetics
196. 2001: A pharmacogenomics odyssey
197. Pharmacogenetic screening for susceptibility to fetal malformations in women